These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 21931838)

  • 1. Gefitinib induces epidermal growth factor receptor dimers which alters the interaction characteristics with ¹²⁵I-EGF.
    Björkelund H; Gedda L; Barta P; Malmqvist M; Andersson K
    PLoS One; 2011; 6(9):e24739. PubMed ID: 21931838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing the epidermal growth factor interaction with four different cell lines: intriguing effects imply strong dependency of cellular context.
    Björkelund H; Gedda L; Andersson K
    PLoS One; 2011 Jan; 6(1):e16536. PubMed ID: 21304974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Significant increase in hEGF uptake is correlated with formation of EGFR dimers induced by the EGFR tyrosine kinase inhibitor gefitinib.
    He P; Li G
    Cancer Chemother Pharmacol; 2013 Aug; 72(2):341-8. PubMed ID: 23748900
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.
    Anido J; Matar P; Albanell J; Guzmán M; Rojo F; Arribas J; Averbuch S; Baselga J
    Clin Cancer Res; 2003 Apr; 9(4):1274-83. PubMed ID: 12684395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor competes with EGF receptor inhibitors to induce cell death in EGFR-overexpressing tumor cells.
    Song JY; Lee SW; Hong JP; Chang SE; Choe H; Choi J
    Cancer Lett; 2009 Oct; 283(2):135-42. PubMed ID: 19380191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sialylation of EGFR by the ST6Gal-I sialyltransferase promotes EGFR activation and resistance to gefitinib-mediated cell death.
    Britain CM; Holdbrooks AT; Anderson JC; Willey CD; Bellis SL
    J Ovarian Res; 2018 Feb; 11(1):12. PubMed ID: 29402301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gefitinib targets EGFR dimerization and ERK1/2 phosphorylation to inhibit pleural mesothelioma cell proliferation.
    Favoni RE; Pattarozzi A; Lo Casto M; Barbieri F; Gatti M; Paleari L; Bajetto A; Porcile C; Gaudino G; Mutti L; Corte G; Florio T
    Curr Cancer Drug Targets; 2010 Mar; 10(2):176-91. PubMed ID: 20088784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antitumor effect in medulloblastoma cells by gefitinib: Ectopic HER2 overexpression enhances gefitinib effects in vivo.
    Meco D; Servidei T; Riccardi A; Ferlini C; Cusano G; Zannoni GF; Giangaspero F; Riccardi R
    Neuro Oncol; 2009 Jun; 11(3):250-9. PubMed ID: 19033425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The EGFR inhibitor gefitinib suppresses ligand-stimulated endocytosis of EGFR via the early/late endocytic pathway in non-small cell lung cancer cell lines.
    Nishimura Y; Bereczky B; Ono M
    Histochem Cell Biol; 2007 May; 127(5):541-53. PubMed ID: 17361439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation.
    Ono M; Hirata A; Kometani T; Miyagawa M; Ueda S; Kinoshita H; Fujii T; Kuwano M
    Mol Cancer Ther; 2004 Apr; 3(4):465-72. PubMed ID: 15078990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors.
    Lichtner RB; Menrad A; Sommer A; Klar U; Schneider MR
    Cancer Res; 2001 Aug; 61(15):5790-5. PubMed ID: 11479217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modular anti-EGFR and anti-Her2 targeting of SK-BR-3 and BT474 breast cancer cell lines in the presence of ErbB receptor-specific growth factors.
    Diermeier-Daucher S; Breindl S; Buchholz S; Ortmann O; Brockhoff G
    Cytometry A; 2011 Sep; 79(9):684-93. PubMed ID: 21786419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
    Servidei T; Riccardi A; Mozzetti S; Ferlini C; Riccardi R
    Int J Cancer; 2008 Dec; 123(12):2939-49. PubMed ID: 18803287
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evidence for efficient phosphorylation of EGFR and rapid endocytosis of phosphorylated EGFR via the early/late endocytic pathway in a gefitinib-sensitive non-small cell lung cancer cell line.
    Nishimura Y; Yoshioka K; Bereczky B; Itoh K
    Mol Cancer; 2008 May; 7():42. PubMed ID: 18492291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor inhibition modulates the nuclear localization and cytotoxicity of the Auger electron emitting radiopharmaceutical 111In-DTPA human epidermal growth factor.
    Bailey KE; Costantini DL; Cai Z; Scollard DA; Chen Z; Reilly RM; Vallis KA
    J Nucl Med; 2007 Sep; 48(9):1562-70. PubMed ID: 17704253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gefitinib ('Iressa', ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2.
    Nutt JE; Lazarowicz HP; Mellon JK; Lunec J
    Br J Cancer; 2004 Apr; 90(8):1679-85. PubMed ID: 15083203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation.
    Jain A; Penuel E; Mink S; Schmidt J; Hodge A; Favero K; Tindell C; Agus DB
    Cancer Res; 2010 Mar; 70(5):1989-99. PubMed ID: 20160029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of cultured glioma cells with the EGFR-TKI gefitinib ("Iressa", ZD1839) increases the uptake of astatinated EGF despite the absence of gefitinib-mediated growth inhibition.
    Sundberg AL; Almqvist Y; Tolmachev V; Carlsson J
    Eur J Nucl Med Mol Imaging; 2003 May; 30(5):727-9. PubMed ID: 12740721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Luteolin and gefitinib regulation of EGF signaling pathway and cell cycle pathway genes in PC-3 human prostate cancer cells.
    Markaverich BM; Vijjeswarapu M; Shoulars K; Rodriguez M
    J Steroid Biochem Mol Biol; 2010 Oct; 122(4):219-31. PubMed ID: 20558290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of epidermal growth factor (EGF)/transforming growth factor-alpha by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice.
    Wu W; O'Reilly MS; Langley RR; Tsan RZ; Baker CH; Bekele N; Tang XM; Onn A; Fidler IJ; Herbst RS
    Mol Cancer Ther; 2007 Oct; 6(10):2652-63. PubMed ID: 17913856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.